Peter the Bridge, Saint Petersburg, Russia

NEOMED Institute Appoints New Vice President, Business Development

November 10th, 2015 |Announcement| No Comments

Press Release

Montreal, Quebec, November 10, 2015 – NEOMED Institute is pleased to announce the addition of Daniel C. Böck to its management team as Vice President, Business Development. He will be primarily responsible for finding and realizing strategic partnerships and/or collaborations around NEOMED’s late-stage programs, while also looking for earlier-stage opportunities from either academia or research institutions to ensure continuity in NEOMED’s pipeline. Additionally, Mr. Böck will be playing a key role in publicizing the NEOMED Institute and its unique multidisciplinary approach in addressing the considerable gap between basic research and the commercialization of new medicines.

Mr. Böck brings over 20 years of industry experience to the NEOMED Institute, most recently as Director, Business Development at GlaxoSmithKline (GSK) in Canada, where he sought to identify acquisition, licensing, and/or distribution opportunities for the Canadian market as well as roll out the GSK Canada Innovation Fund intended to strategically invest in, and financially support, innovative research within the Canadian life sciences industry. Mr. Böck has also held the position of Vice President, Business Development in a small, Montreal-based biotechnology company and so has an appreciation for, and understanding of, both big pharma and small biotech perspectives. Over the span of his career, he has held roles with either regional or worldwide responsibilities in sales, product management, marketing, venture capital, and business development.

Mr. Böck holds a PhD degree in Microbiology.


The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.

The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.

For more information, please visit our website:



For more information, please contact:

Rachel Cogdell
Communications Coordinator
NEOMED Institute
7171 Frederick-Banting
Montreal, Quebec H4S 1Z9
514-367-1212 x 209

Share this

Similar News

image articles
10 April 2018

NEOMED Therapeutics 1 names Dr. Frank Giles as Chief Medical Officer

Read complete news
image articles
28 February 2018

NEOMED Institute Launches NEOMED Therapeutics 1 Inc. to fund and develop a dual BET inhibitor anticancer therapy pipeline with NEO2734, an oral dual BET and CBP/P300 inhibitor, as lead compound

Read complete news
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia